ABMD News and Press, ABIOMED Inc. From 11/01/22

ABIOMED Inc ( NASDAQ: ABMD ) opened about 50% up on Tuesday after Johnson & Johnson ( NYSE: JNJ ) said it will buy the heart pump maker for $16.6 billion. ABIOMED stock shot up in line with the proposed premium J&J is willing to pay $380 a share for the medical d...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Proxima Studio / Shutterstock.com Uber (NYSE: UBER ) stock is on the move Tuesday as investors react to results from the ride-sharing company’s earnings report for the third quarter of 2022 . T...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Jonathan Weiss / Shutterstock.com Carvana (NYSE: CVNA ) stock is climbing higher on Tuesday after JPMorgan analyst Rajat Gupta upgraded the company’s shares. That upgrade has the JPMorgan analys...

Johnson & Johnson ( NYSE: JNJ ) is said to have approached Abiomed ( NASDAQ: ABMD ) about a transaction before a deal was eventually struck. Johnson ( JNJ ) reached out to Abiomed ( ABMD ) to start deal talks, according to CNBC's David Faber. Abiomed sh...

The stock market has been increasingly turbulent in recent weeks, and investors are hopeful that an old seasonal adage will prove to be a turning point in the current bear market. With the historically crash-prone October now over, market participants often hope for an end-of-year rally. Th...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! Moving stocks this morning are earnings reports, talk of changes to lo...

Abiomed press release ( NASDAQ: ABMD ): FQ2 Non-GAAP EPS of $1.30 beats by $0.27 . Revenue of $265.92M (+7.2% Y/Y) misses by $6.83M; an increase of 11% in constant currency. Gross margin of 81.6% compared to 82.3% in the same period of the prior fiscal year. ...

ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial Highlights: Revenue of $266 million, an increase of 11% in constant...

Strengthens Johnson & Johnson’s MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance Johnson & Johnson’s Near- and Long...

The U.S. Food and Drug Administration (FDA) granted pre-market approval (PMA) to Abiomed's ( NASDAQ: ABMD )  Impella RP Flex with SmartAssist to treat acute right heart failure for up to 14 days. According to the FDA, PMA is the most stringent type of device ma...